Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by A. Huizing.
Journal of Medicinal Chemistry | 2015
A. Huizing; Milon Mondal; Anna K. H. Hirsch
Plasmepsins (Plms) are aspartic proteases involved in the degradation of human hemoglobin by Plasmodium falciparum. Given that the parasite needs the resulting amino acid building blocks for its growth and development, plasmepsins are an important antimalarial drug target. Over the past decade, tremendous progress has been achieved in the development of inhibitors of plasmepsin using two strategies: structure-based drug design (SBDD) and structure-based virtual screening (SBVS). Herein, we review the inhibitors of Plms I-IV developed by SBDD or SBVS with a particular focus on obtaining selectivity versus the human Asp proteases cathepsins and renin and activity in cell-based assays. By use of SBDD, the flap pocket of Plm II has been discovered and constitutes a convenient handle to obtain selectivity. In SBVS, activity against Plms I-IV and selectivity versus cathepsins are not always taken into account. A combination of SBVS, SBDD, and molecular dynamics simulations opens up opportunities for future design cycles.
Journal of Medicinal Chemistry | 2014
Xiaoyun Zhou; Shivashankar Khanapur; A. Huizing; Rolf Zijlma; Marianne Schepers; Rudi A. J. O. Dierckx; Aren van Waarde; Erik F. J. de Vries; Philip H. Elsinga
2-(2-Furanyl)-7-[2-[4-[4-(2-[(11)C]methoxyethoxy)phenyl]-1-piperazinyl]ethyl]7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine-5-amine [(11)C]-3 ([(11)C]Preladenant) was developed for mapping cerebral adenosine A2A receptors (A2ARs) with PET. The tracer was synthesized in high specific activity and purity. Tissue distribution was studied by PET imaging, ex vivo biodistribution (BD), and in vitro autoradiography (ARG) experiments. Regional brain uptake of [(11)C]-3 was consistent with known A2ARs distribution, with highest uptake in striatum. The results indicate that [(11)C]-3 has favorable brain kinetics and exhibits suitable characteristics as an A2AR PET tracer.
Archive | 1995
W. Bouman; A. Huizing; E. Koster; J. Mink; M. Oliehoek; L.E.J. Pels Rijcken; E.J. de Vries
Business Reengineering op doorreis: tussenstation of eindstation? | 1997
C. Ciborra; E.J. de Vries; A. Huizing
Tijdschrift voor Bedrijfsadministratie | 1998
A. Huizing; E.J. de Vries
Business reengineering op doorreis: tussenstation of eindstation? | 1997
J.J. Boonstra; E.J. de Vries; A. Huizing
Associatie Nieuwsbrief | 1997
A. Huizing; E.J. de Vries
Anticancer Research | 1997
E. Koster; E.J. de Vries; A. Huizing
ACM Sigsoft Software Engineering Notes | 1997
E.J. de Vries; A. Huizing
Computable | 1995
E.J. de Vries; A. Huizing